Taligen is at the forefront of developing targeted therapies that regulate the complement system to treat inflammatory and immune diseases in a whole new way.

Based on unique insights and proprietary technology, Taligen’s novel biologic drugs intervene at key points in the complement system, a potent and ubiquitous immune pathway that, in the past, has been difficult to effectively regulate … until now.

Taligen’s proprietary platform enables the development of therapeutics which selectively identify and are precisely directed to the cell surface of inflammatory tissues where they naturally and broadly control inflammation.

LATEST NEWS

November 10, 2009 - Taligen Therapeutics Announces that TT30, a Novel Protein Targeting the Complement System, will be Highlighted in Two Presentations at the American Society of Hematology Meeting

December 5, 2008 - Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

October 6, 2008 - In Vivo Data on Taligen Therapeutics’ Pipeline Candidates Presented at the XXII International Complement Workshop

More News...

Taligen Fact Sheet